Disclosed herein is the use of an effective amount of ã-D-glutamyl-L-tryptophan (also referred to as SCV-07) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for reducing the amount of mucosal deterioration, injury or damage to at least one of oral and esophageal mucosal tissues, the mucosal deterioration, injury or damage resulting from radiation therapy for head and neck cancer.
